The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Paclitaxel, ifosfamide, cisplatin (TIP) in patients with advanced urethral adenocarcinoma: A single center, retrospective analysis.
 
Gwanhyun Park
No Relationships to Disclose
 
Inkeun Park
Consulting or Advisory Role - Astellas Pharma Korea; Boryung Pharmaceuticals; Chong Kun Dang Pharmaceutical Co; Janssen
Research Funding - Boryung Pharmaceutical Co (Inst); Chong Kun Dang Pharmaceutical Co. (Inst)
 
Shinkyo Yoon
No Relationships to Disclose
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)